<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>在Biontech期II试验中给药的第一个患者mRNA癌疫苗 First patient dosed in BioNTech Phase II trial of mRNA cancer vaccine</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script>
<script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">First patient dosed in BioNTech Phase II trial of mRNA cancer vaccine<br/>在Biontech期II试验中给药的第一个患者mRNA癌疫苗 </h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2021-06-19 09:51:48</div><div class="story_img_container"><a href="http://img2.diglog.com/img/2021/6/0df4a8b8d879e968da2daac42d6b79ea.jpg"><img src="http://img2.diglog.com/img/2021/6/0df4a8b8d879e968da2daac42d6b79ea.jpg" class="img-fluid my_story_img" onerror="this.style.display='none'"></a></div><div class="page_narrow text-break page_content"><p>The first patient has been treated in a Phase II cancer vaccine trial by BioNTech, evaluating its mRNA-based therapy BNT111 in combination with Libtayo (cemiplimab) in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma. The open-label randomised trial will assess the efficacy, tolerability and safety of BNT111 in combination with Libtayo. It will enrol 120 patients and will evaluate the effects of the combination, as well as stand-alone individual agents. BNT111 is the lead product candidate from BioNTech’s FixVac platform and targets a fixed combination of mRNA-encoded, tumour-associated antigens, with the aim of activating a strong and precise immune response against cancer.     The candidate is fully owned by BioNTech while Libtayo, an anti-PD-1 monoclonal antibody, is being co-developed by Regeneron and Sanofi. “BNT111 is an intravenous therapeutic cancer vaccine candidate encoding for a fixed set of four cancer-specific antigens optimised for immunogenicity and delivered as RNA-lipoplex formulation,” says BIoNTech. According to the firm, more than 90% of melanomas in patients express at least one of the four tumour-associated antigens encoded in BNT11; NY-ESO-1, MAGE-A3, tyrosinase and TPTE.   The BNT111-01 trial, which is being carried out in collaboration with Regeneron, was reviewed and approved by the regulatory authorities in EU countries Spain, Germany, Italy and Poland as well as in the UK, the US and Australia. The first patient has been dosed in the EU. The primary endpoint of the study is to assess the overall response rate of BNT111 in combination with Libtayo. Secondary endpoints include overall response rate in the single-agent arms, duration of response and safety. “Our vision is to harness the power of the immune system against cancer and infectious diseases. We were able to demonstrate the potential of mRNA vaccines in addressing Covid-19. We must not forget, that cancer is also a global health threat, even worse than the current pandemic,” said BioNTech’s co-founder and CMO Özlem Türeci. “BNT111 has already shown a favourable safety profile and encouraging preliminary results in early clinical evaluation. With the start of patient treatment in our Phase II trial, we are encouraged to continue on our initial path to realise the potential of mRNA vaccines for cancer patients.”    This Phase II trial is based on previous results from the Phase I Lipo-MERIT dose-escalation trial that confirmed a favourable safety profile in 89 patients with advanced melanoma. Additionally, efficacy analysis of the Lipo-MERIT study in a subset of 42 metastatic melanoma patients treated earlier with a checkpoint-inhibitor demonstrated that BNT111 mediated durable responses, both as a single agent and in combination with anti-PD-1 antibodies. Durable objective responses by BNT111 were associated with activation and strong expansion of tumor-antigen-specific CD4+ and CD8+ T cells. These results were published in   Nature in July 2020. BioNTech also plans to start randomised Phase II trials with mRNA vaccine product candidates in two additional programs in 2021. “As part of its development strategy, BioNTech aims to rapidly advance its broad oncology pipeline and expects to bring additional candidates into late-stage clinical development and towards market entry within the next five years,” said the firm.</p><p>第一个患者已在Biontech中的II期癌症疫苗试验中治疗，将其基于mRNA的治疗BNT111与LibtaYo（Cemiplimab）组合的抗PD1-难治/复发的不可切除阶段III或IV黑色素瘤的组合。开放标签随机试验将评估BNT111与Libtayo的疗效，耐受性和安全性。它将注册120名患者，并将评估组合的影响，以及独立的个体代理商。 BNT111是Biontech FixVac平台的铅产品候选者，并针对MRNA编码，肿瘤相关抗原的固定组合，目的是激活对癌症的强烈和精确的免疫应答。候选人由Biontech完全拥有，而Libtayo是一种抗PD-1单克隆抗体，是由Regeneron和Sanofi共同开发的。 “BNT111是一种静脉治疗癌症疫苗候选候选，用于固定的四组癌症特异性抗原针对免疫原性优化并作为RNA-Lipoplex制剂递送，”Biontech说。据该公司据稳定，90％以上的患者黑素瘤表达了BNT11中编码的四种肿瘤相关抗原中的至少一种; NY-ESO-1，MAGE-A3，酪氨酸酶和TPTE。监管机构在欧盟国家西班牙，德国，意大利和波兰以及英国，美国和澳大利亚的监管机构进行审查和批准，正在与Regeneron合作进行的BNT111-01试验。第一个患者已在欧盟服用。该研究的主要终点是评估BNT111与Libtayo组合的总响应率。辅助端点包括单代理臂，响应持续时间和安全的总体响应速率。 “我们的愿景是利用免疫系统免受癌症和传染病的力量。我们能够证明MRNA疫苗在寻址Covid-19中的潜力。我们不能忘记，癌症也是一个全球健康威胁，甚至比目前的大流行更糟糕，“Biontech的联合创始人和CMOÖzlemTüreci说。 “BNT111已经显示出有利的安全性，并鼓励早期临床评估的初步结果。随着患者治疗的开始，我们鼓励我们继续在我们的初始路径上实现癌症患者mRNA疫苗的潜力。“该第二阶段审判基于先前的脂肪MINMIT剂量 - 升级试验中的先前结果，该试验证实了89例高级黑素瘤患者有利的安全性。另外，用检查点抑制剂早期治疗的42例转移性黑色瘤患者的血脂的疗效分析证明了BNT111介导的耐用反应，无论是单一的药剂还是与抗PD-1抗体组合。 BNT111的耐久性客观反应与肿瘤 - 抗原特异性CD4 +和CD8 + T细胞的激活和强大膨胀有关。这些结果于2020年7月出版了本质上。Biontech还计划在2021年的两个额外方案中开始随机与mRNA疫苗产品候选人试验。“作为其发展战略的一部分，Biontech旨在迅速推进其广泛的肿瘤管道并期望该公司表示，将额外的候选人纳入后期临床开发和市场进入，“该公司表示。 </p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://www.clinicaltrialsarena.com/news/first-patient-dosed-in-biontech-phase-ii-trial-of-mrna-cancer-vaccine/">https://www.clinicaltrialsarena.com/news/first-patient-dosed-in-biontech-phase-ii-trial-of-mrna-cancer-vaccine/</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/mrna/">#mrna</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/dosed/">#dosed</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/癌症/">#癌症</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/谷歌/">#谷歌</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy;2012-2021 diglog.com </div></div></body></html>